{"id":5939,"date":"2025-12-09T12:35:14","date_gmt":"2025-12-09T11:35:14","guid":{"rendered":"https:\/\/amsbiopharma.com\/innovation\/lyctus-development-of-protein-degraders-in-neurological-diseases\/"},"modified":"2025-12-09T12:38:55","modified_gmt":"2025-12-09T11:38:55","slug":"lyctus-development-of-protein-degraders-in-neurological-diseases","status":"publish","type":"project","link":"https:\/\/amsbiopharma.com\/es\/innovation\/lyctus-development-of-protein-degraders-in-neurological-diseases\/","title":{"rendered":"LYCTUS &#8211; Desenvolvemento de degradadores de prote\u00ednas en enfermidades neurol\u00f3xicas"},"content":{"rendered":"<p><img decoding=\"async\" class=\"alignnone wp-image-5934\" role=\"img\" src=\"https:\/\/amsbiopharma.com\/wp-content\/uploads\/XUNTA-positivo.svg\" alt=\"\" width=\"155\" height=\"44\" \/>\u00a0 \u00a0 \u00a0 \u00a0\u00a0 <img decoding=\"async\" class=\"alignnone wp-image-5932\" src=\"https:\/\/amsbiopharma.com\/wp-content\/uploads\/GAHCofinanciadoPOSITIVO-300x65.png\" alt=\"\" width=\"190\" height=\"41\" srcset=\"https:\/\/amsbiopharma.com\/wp-content\/uploads\/GAHCofinanciadoPOSITIVO-300x65.png 300w, https:\/\/amsbiopharma.com\/wp-content\/uploads\/GAHCofinanciadoPOSITIVO-1024x221.png 1024w, https:\/\/amsbiopharma.com\/wp-content\/uploads\/GAHCofinanciadoPOSITIVO-768x166.png 768w, https:\/\/amsbiopharma.com\/wp-content\/uploads\/GAHCofinanciadoPOSITIVO-1536x332.png 1536w, https:\/\/amsbiopharma.com\/wp-content\/uploads\/GAHCofinanciadoPOSITIVO-2048x443.png 2048w\" sizes=\"(max-width: 190px) 100vw, 190px\" \/>\u00a0 \u00a0 \u00a0<img decoding=\"async\" class=\"alignnone wp-image-5930\" src=\"https:\/\/amsbiopharma.com\/wp-content\/uploads\/Logotipos_RGB_FondosEuropeos_Positivo_Castellano-300x63.png\" alt=\"\" width=\"205\" height=\"39\" \/><\/p>\n<p><strong>Obxecto da operaci\u00f3n:<\/strong> Desenvolver unha terapia innovadora contra o ictus isqu\u00e9mico (ACV) e as complicaci\u00f3ns derivadas das t\u00e9cnicas de reperfusi\u00f3n, como a transformaci\u00f3n hemorr\u00e1xica (TH), mediante o uso de degradadores dirixidos de prote\u00ednas. Estes degradadores, mAb-LYTACs, son mol\u00e9culas heterobifuncionais compostas por un anticorpo monoclonal (AcM) altamente espec\u00edfico contra unha prote\u00edna de interese e un p\u00e9ptido internalizante que dirixen ditas prote\u00ednas extracelulares \u00e1 degradaci\u00f3n lisosomal.<\/p>\n<p><strong>Resultados perseguidos:<\/strong> completar el desarrollo precl\u00ednico de estos compuestos evaluando, in vitro e in vivo, su Mecanismo de Acci\u00f3n (MoA), biodistribuci\u00f3n, seguridad y eficacia.<\/p>\n<p>Empresa beneficiaria, <strong>l\u00edder da agrupaci\u00f3n<\/strong>: Aptadegrad, S.L.<\/p>\n<p><strong>Outros beneficiarios:<\/strong> AMS Biopharma Laboratory, S.L., Fundaci\u00f3n P\u00fablica Galega Instituto de investigaci\u00f3n Sanitaria de Santiago de Compostela FIDIS, Diversa Technologies, S.L.<\/p>\n<p><strong>Expediente:<\/strong> IN856C 2024\/08<\/p>\n<p>Fechas de ejecuci\u00f3n: 15\/05\/2024 &#8211; 15\/12\/2027<\/p>\n","protected":false},"template":"","class_list":["post-5939","project","type-project","status-publish","hentry","entry"],"_links":{"self":[{"href":"https:\/\/amsbiopharma.com\/es\/wp-json\/wp\/v2\/project\/5939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amsbiopharma.com\/es\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/amsbiopharma.com\/es\/wp-json\/wp\/v2\/types\/project"}],"version-history":[{"count":1,"href":"https:\/\/amsbiopharma.com\/es\/wp-json\/wp\/v2\/project\/5939\/revisions"}],"predecessor-version":[{"id":5940,"href":"https:\/\/amsbiopharma.com\/es\/wp-json\/wp\/v2\/project\/5939\/revisions\/5940"}],"wp:attachment":[{"href":"https:\/\/amsbiopharma.com\/es\/wp-json\/wp\/v2\/media?parent=5939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}